Abstract

Statins display numerous effects independent of their well described lipid-lowering effect that may be of potential benefit in preventing vascular injury and ischemic vascular events. These effects may both prevent and improve vessel wall abnormalities. We review the current literature to provide support that statins may have a modifying effect on the vasculopathy, fibrosis and immune dysregulation observed in systemic sclerosis.

Keywords: Systemic sclerosis, scleroderma, statins, vasculopathy, tissue fibrosis